An observational study in Retinoblastoma, sponsored by French Africa Pediatric Oncology Group. Recruiting at 7 sites in 6 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by French Africa Pediatric Oncology Group · Observational
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.
In this study we will try to improve the outcome for children with stage II disease. It is hoped that we will be able to show that with early intervention correct early diagnosis the survival of these children is greatly improved. The collection of data in this observational study will allow us to show this improvement, by analysis of stage, treatment and outcome.
124 studies on the registry are indexed under Retinoblastoma; 23 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 224 across 34 observational studies indexed under Retinoblastoma.
Browse Retinoblastoma studies →French Africa Pediatric Oncology Group is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
all children presenting at participating units who can be treated
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
Number of cases with retinoblastoma in each participating hospital.
Evaluation of the number of cases registered .
Time frame: 10 years
Number of cases with stage 2 disease
Evaluation of the number of cases registered with stage 2 disease.
Time frame: 10 years
Feasibility of these therapeutic recommendations in an African setting
Evaluate the application of these therapeutic recommendations
Time frame: 10 years
Evaluating the treatment given.
Comparison of treatment given and recommended treatment.
Time frame: 10 years
follow up
analysis of the number of children alive or dead after treatment
Time frame: 10 years
Started Nov 2020 (actual). Primary completion is estimated for Dec 2028, 97 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Africa Pediatric Oncology Group